Search results
Author(s):
Barry Borlaug
Added:
1 year ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,…
View more
The Role of GLP-1 in Heart Failure
Author(s):
Amina Rakisheva
,
Anton Zatsarinnyy
Added:
4 months ago
Editorial
Obesity Definitions and LOS in Heart Failure
Author(s):
Michał Czapla
,
Christopher S Lee
,
Maria Jędrzejczyk
,
et al
Added:
2 weeks ago
Original Research
Added:
10 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
SGLT-2 Inhibitors and Heart Failure
Author(s):
C Noah Nilsson
,
Mads Kristian Ersbøll
,
Finn Gustafsson
Added:
1 year ago
Review Article
Author(s):
Dominic Marcel Alfonso
Added:
3 months ago
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s):
Rishi Sethi
,
Pravesh Vishwakarma
,
Akshyaya Pradhan
Added:
1 year ago
Review Article
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s):
Giovanni Battista Bonfioli
,
Matteo Pagnesi
,
Daniela Tomasoni
,
et al
Added:
10 months ago
Review Article
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s):
Anastasia Shchendrygina
,
Amina Rakisheva
,
Ilya Giverts
,
et al
Added:
1 year ago
Review Article
Author(s):
Andrew JS Coats
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more